Jacqueline Trussell
Acute Care · Portland, ORNPI 1982040291
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,540 of the $15,071 with a category attached, or 69.9%. Johnson & Johnson accounts for 92.1% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $14,017, more than ten times the $121 reported in 2023. Among acute care clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $264.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$14K
- Servier Pharmaceuticals LLC$224
- Bristol Myers Squibb$141
- Janssen Scientific Affairs, LLC$136
- Sanofi$125
- E.r. Squibb & Sons, L.L.C.$122
- plus $446 from 8 others
What the payments were for
- Speaking & faculty fees$10,54070%
- Travel & lodging$2,31315%
- Food & beverage$2,13414%
- Education$841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 34 | $13,876 |
| Servier Pharmaceuticals LLC | 2 | $224 |
| Bristol Myers Squibb | 2 | $141 |
| Janssen Scientific Affairs, LLC | 6 | $136 |
| Sanofi | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Amgen | 1 | $122 |
| AstraZeneca | 1 | $81 |
| Genmab U.S., Inc. | 1 | $66 |
| Legend Biotech USA Inc. | 3 | $55 |
| Gilead | 2 | $43 |
| Adaptive Biotechnologies Corporation | 1 | $36 |
| Adaptimmune LLC | 1 | $24 |
| AbbVie | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,071 in reported general payments places this provider in the 95th percentile of 105 acute care providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $9,846 |
| Gabapentin | 17 | $379 |
| Acyclovir | 15 | $357 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 40 | $312 |
| Omeprazole | 20 | $196 |
| Celecoxib | 13 | $122 |
| Lorazepam | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Other acute care in Portland
- Robin MillerPortland$74K
- Lina Rossetti-GrulichPortland$8K
- Aura PetcuPortland$3K
- Jamie FungPortland$2K
- Amy AlbertsPortland$2K
- Lynzy Elzinga WeekesPortland$2K
- Benjamin HartwigPortland$1K
- Kristyn DemelloPortland$1K
- Dana MoussalliPortland$1K
- Melissa SkinnerPortland$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.